RxDoctor Payments DataLook up a doctor →

Rana Zabad, MD

Neurology · Omaha, NENPI 1235316290

Payments from drug & device makers

$1,260,235in general payments, 2019–2025

Across 432 payments — averaging $2917.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$435K
  • EMD Serono, Inc.$227K
  • Sanofi$157K
  • Adamas Pharmaceuticals, Inc.$142K
  • TG Therapeutics, Inc.$89K
  • Genentech USA, Inc.$71K
  • plus $139K from 10 others

What the payments were for

  • Consulting fees$140,47351%
  • Speaking & faculty fees$100,21736%
  • Travel & lodging$27,60110%
  • Food & beverage$7,6003%
  • Education$560%
  • Gifts$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260,235 in reported general payments places this provider in the 95th percentile of 105 neurology providers in Nebraska.

See all neurology providers in Nebraska

Medicare billing

Part B allowed, 2024
$33,281
Medicare patients
145
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate88$461,832
Kesimpta PenOfatumumab48$445,031
AubagioTeriflunomide33$297,918
Glatiramer Acetate54$119,785
AustedoDeutetrabenazine22$97,437
Teriflunomide148$93,919
Dimethyl Fumarate40$66,606
Dalfampridine ErDalfampridine206$66,598
FingolimodFingolimod Hcl72$64,769
GlatopaGlatiramer Acetate20$42,539
NuedextaDextromethorphan Hbr/Quinidine23$28,760
BriviactBrivaracetam14$22,758
MyrbetriqMirabegron18$17,207
Baclofen169$4,982
Gabapentin157$3,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$156,894$297,91833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 neurology providers in Nebraska.

Other neurology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →